Johnson & Johnson’s decision to splash out $14.6 billion on its purchase of Intra-Cellular Therapies earlier this year was largely driven by the acquired company's rising antipsychotic star Caplyta ...

Enhancing Signal Detection and Mitigating Placebo Response in Major Depressive Disorder Clinical Trials, Upcoming Webinar Hosted by Xtalks ...

While forging ahead in this year’s #FierceMadness Drug Ad Tournament, Intra-Cellular Therapies’ Caplyta has ginned up what analysts view as a sweeping trial win in two distinct mood disorders. Caplyta ...

The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults. This approval marks ...

Flow Neuroscience announced that the FDA approved its Flow at-home brain stimulation device for treating major depressive ...

“Unspecified depressive disorder” is used when someone displays depressive symptoms, but there isn’t enough information for a specific diagnosis. Depressive symptoms can be complex and may not clearly ...

A depression drug candidate that’s a key part of Johnson & Johnson’s neuroscience strategy has failed a Phase 3 clinical trial, the latest dose of disappointing news for an emerging class of medicines ...

A new study suggests treatment-resistant depression may be rooted in the immune system. Trauma, stress biology, and mini-brain models reveal a hidden neuroimmune story.

Dealing with mental health conditions like depression can be challenging. Some people struggle to find the right treatment or combination of treatments for their condition. In major depression ...

Please provide your email address to receive an email when new articles are posted on . Spravato is the first monotherapy for adults with major depressive disorder who had an inadequate response to at ...